Alaunos Therapeutics (TCRT) CEO granted 4,363 shares in lieu of cash salary

Q: At what price was the Alaunos Therapeutics (TCRT) CEO stock grant valued?

The stock grant to CEO Holger Weis was valued at $2.01 per share , representing the per-share value used for the 4,363-share issuance in lieu of net salary.

Q: Does the Alaunos Therapeutics (TCRT) CEO Form 4 involve a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as a plan transaction . The reported event is a stock issuance in lieu of net salary , not an open-market trade under a plan.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Alaunos Therapeutics, Inc. reported that CEO Holger Weis received a grant of common stock as part of his compensation. On 2026-08-06, he acquired 4,363 shares of common stock at a value of $2.01 per share, issued in lieu of net salary. Following this stock issuance, Weis directly owns 25,483 shares of Alaunos Therapeutics common stock.

Insider Trade Summary

Net Buyer: 4,363 shares

Net Buy 1 txn

Insider Weis Holger

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock ^F1	4,363	$2.01	$9K

Holdings After Transaction: Common Stock — 25,483 shares (Direct)

Footnotes (1)

F1. Represents shares of common stock issued in lieu of net salary.

Key Figures

Shares granted: 4,363 shares Grant valuation price: $2.01 per share Post-transaction holdings: 25,483 shares

3 metrics

Shares granted 4,363 shares Common stock issued to CEO Holger Weis on 2026-08-06 in lieu of net salary

Grant valuation price $2.01 per share Per-share value for the 4,363-share issuance to the CEO

Post-transaction holdings 25,483 shares Total direct common stock holdings of CEO Holger Weis after the grant

Key Terms

in lieu of net salary, Grant, award, or other acquisition, direct ownership

3 terms

in lieu of net salary financial

"Represents shares of common stock issued in lieu of net salary."

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

direct ownership financial

"ownership_type marked as direct for the reported shares"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 04:15 PM Accepted by SEC EDGAR 08/11/2026 - 04:15 PM

FAQ

What insider transaction did Alaunos Therapeutics (TCRT) report for its CEO?

Alaunos Therapeutics reported that CEO Holger Weis received 4,363 shares of common stock on 2026-08-06 as a grant issued in lieu of net salary.

At what price was the Alaunos Therapeutics (TCRT) CEO stock grant valued?

The stock grant to CEO Holger Weis was valued at $2.01 per share, representing the per-share value used for the 4,363-share issuance in lieu of net salary.

How many Alaunos Therapeutics (TCRT) shares does the CEO hold after this transaction?

After receiving the stock issued in lieu of salary, CEO Holger Weis directly holds 25,483 shares of Alaunos Therapeutics common stock, as reported following the 2026-08-06 grant.

Was the Alaunos Therapeutics (TCRT) CEO Form 4 transaction a market purchase or sale?

The Form 4 shows no market purchase or sale. CEO Holger Weis acquired 4,363 shares as a grant in lieu of net salary, rather than through open-market trading.

Does the Alaunos Therapeutics (TCRT) CEO Form 4 involve a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as a plan transaction. The reported event is a stock issuance in lieu of net salary, not an open-market trade under a plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weis Holger

(Last)

(First)

(Middle)

501 E LAS OLAS BLVD

SUITE 300

(Street)

FORT LAUDERDALE

FLORIDA

33301

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/06/2026		A		4,363⁽¹⁾	A	$2.01	25,483	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock issued in lieu of net salary.

	Weis Holger	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR